Video

Dr. Rule on the Next Steps for BTK Inhibitors in MCL

Author(s):

Simon Rule, MD, professor of hematology, University of Plymouth, discusses the next steps for ibrutinib (Imbruvica) and other BTK inhibitors in the treatment landscape of mantle cell lymphoma (MCL).

Simon Rule, MD, professor of hematology, University of Plymouth, discusses the next steps for ibrutinib (Imbruvica) and other BTK inhibitors in the treatment landscape of mantle cell lymphoma (MCL).

At the 2019 ASH Annual Meeting, 7.5-year follow-up data from a pooled analysis showed that ibrutinib led to more favorable responses versus chemotherapy in patients with relapsed/refractory MCL. There are also data with the combination of ibrutinib and venetoclax (Venclexta) in the relapsed/refractory setting.

The data that Rule presented at the meeting showed that ibrutinib led to high response rates in asymptomatic patients. As such, Rule believes the next step will be to move ibrutinib and other BTK inhibitors into earlier lines of treatment.

Several trials are evaluating the use of ibrutinib in the frontline setting. One such trial in the United Kingdom is evaluating the combination of ibrutinib and rituximab (Rituxan) versus chemotherapy in older patients. Moreover, an ongoing trial is evaluating ibrutinib plus venetoclax and obinutuzumab (Gazyva). To date, 14 out of 15 patients had minimal residual disease—negative complete remissions. With further study, chemotherapy may not be necessary in the up-front setting, concludes Rule.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity